Login

Immune-monitoring of Cancer and Immune-mediated Pathologies Unit (UICPI)

In the context of immune-mediated pathologies and especially those associated with malignancy, adequate immunological monitoring is essential to explain what is happening in a specific patient, to help establish specific predictive biomarkers of response and follow-up that optimise treatment costs and avoid adverse effects; even more so considering that immunotherapy has dramatically transformed the prognosis of various fields of medicine with the forecast of an exponential development in the coming years,

Immuno-monitoring of Cancer and Immune-mediated Pathologies Unit (UICPI) represents a multidisciplinary platform coordinated by the Immunology Department, which offers its expertise in a range of immuno-monitoring techniques for the correct design and interpretation of the results of multiple parameters (Immunoscore) and to achieve a better approach to prevention, diagnosis, treatment, and follow-up for each individual patient.  This STU works in coordination with the Immunogenetics and Sequencing Unit for the study of the TCR repertoire, spectrotypes, quantitative PCR for the study of cytokines and checkpoint studies, as well as with the Medical Oncology Service and the Oncology Phase I Unit.

To this end the Unit is divided into:

  • Specific immunophenotyping studies of malignancy and immune-mediated pathologies.
  • Specific response and effectiveness vs. autoimmunity studies
  • Specific tolerance induction studies.

To this end, the following general objectives are pursued:

  • Typing of the pathological immunophenotype prior to treatment initiation and monitoring associated with clinical intervention.
  • Multiparametric integrated assessment of the specific immune response to specific antigens (immunisation) or to a specific immunotherapy.
  • Correlation of the presence and magnitude of response to treatment with clinical data.
  • Recognition of appropriate populations for the study of vaccines or tolerogenic treatments.
  • Appropriate identification for the selection of patients matched to the most optimal immunotherapy (personalised immunotherapy).
  • Establishing a better clinical response based on precision medicine

+ Info

  • Responsible:

    Dra. Silvia Sánchez Ramón

    ssramon@salud.madrid.org

    Tel. +34 913303000 Ext. 484692

  • Coordinator:

    Nabil Alberto Shubi-Issa Marín

  • Collaborating members:

    Dr. Pedro Pérez Segura

    Dr. Alberto Ocaña

    Dr. Miguel Fernández Arquero

    Teresa Guerra Galán

    Daniel Tovar Manzano

  • 1ª Sur. Servicio de Inmunología. Laboratorio de Inmunidad Celular.
    Hospital Clínico San Carlos
    C/ Profesor Martín Lagos s/n.
    28040 Madrid

Services offered

  • Immunophenotyping and functional study of antigen-specific subpopulations: activation, proliferation, cytokine production, Th1/Th2/Th17, among others.
  • Phenotypic and phosphoflow analysis (flow cytometry)
  • Study of TRECs in screening for secondary immunodeficiencies.
  • Cytokine and chemokine profiling studies after antigen-specific stimulation.
  • Inflammation vs. immunoregulation (Luminex)
  • Studies of secondary and primary immunodeficiencies associated with malignancy:
    Typing of the pathological immunophenotype and prediction of risk associated with immunodeficiency and monitoring of response to treatment.
  • Specific immune response to target antigens:
    Lymphoproliferative and antigen-specific cell stimulation studies.
    Antigen-specific cytotoxicity studies.
    Tetramer or pentamer assays for specific HLA-restricted response.
    Study of specific cell populations for the development of vaccines or tolerogenic treatments.
  • Humoral response to drugs:
    Determination of specific anti-drug antibodies by ELISA or immunoluminescence (real-time).
  • Centralisation of results and support in data analysis: multidimensional analysis, phenograms, meta-clustering of lymphocyte subpopulations.

The Biobank is attached to 2 external committees:

    Sección 1 Solicitante:

      • Sección 2 Proyecto:

      • Sección 3 Muestras:

      I-DONANTE

      • II-DONACIÓN

      • III-MUESTRAS